Healthcare 2 March 2026 - 29 March 2026

Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding

Serve Robotics Stock Drops Before Long Weekend, Hospital Project Still Needs Funding

Serve Robotics Inc. shares fell 1.25% to $8.70 Friday, underperforming a record-setting Dow, then ticked up to $8.73 after hours. Volume reached 3.84 million shares, with a market value near $673 million. Investors weighed rapid revenue growth and a new hospital robotics push against funding and execution risks ahead of the Memorial Day market holiday.
May 22, 2026
4DMedical Ltd Wins EU CE Mark, Raises A$83 Million as Mayo Clinic Deal Boosts CT:VQ Push

4DMedical Ltd Wins EU CE Mark, Raises A$83 Million as Mayo Clinic Deal Boosts CT:VQ Push

4DMedical said Friday its CT:VQ lung imaging software won CE mark clearance in the EU and secured A$83 million in a private placement at A$5.90 a share. The company expects to have A$289 million in cash at year-end 2025. Mayo Clinic began using CT:VQ on March 25, joining five other U.S. academic centers since FDA clearance in September. Shares closed at A$6.28 after touching A$7.55 intraday.
March 29, 2026
GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects

GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects

GSK shares rose 0.54% to 2,056 pence in London after the European Medicines Agency agreed to review its experimental hepatitis B drug, bepirovirsen. The company said Phase III trials showed higher functional cure rates when bepirovirsen was added to standard care. The drug is not yet approved. JPMorgan maintained a sell rating, with a target price near current levels.
March 27, 2026
GSK Stock Price Today: Shares Jump on Japan Orphan-Drug Nod

GSK Stock Price Today: Shares Jump on Japan Orphan-Drug Nod

GSK shares climbed 3.2% to 2,039.5 pence in London after Japan granted orphan-drug status to its lung-cancer therapy risvutatug rezetecan and a filing showed continued share buybacks. The stock rose above 2,000 pence, aided by broader FTSE 100 gains. Analysts at Deutsche Bank and Barclays maintained price targets below current levels, citing mixed signals from recent drug launches.
March 25, 2026
CSL Limited Breaks Ground on $1.5 Billion Illinois Plant as Turnaround Pressure Builds

CSL Limited Breaks Ground on $1.5 Billion Illinois Plant as Turnaround Pressure Builds

CSL Limited has begun a $1.5 billion expansion of its Kankakee, Illinois, manufacturing site, aiming to add at least 300 jobs and boost plasma-derived therapy output by 2031. The move follows an 81% drop in first-half profit and recent leadership changes. CSL also repurchased 62,472 shares for about A$9.1 million on March 10. Shares closed at A$144.56 Tuesday, up 1.65% but near a 52-week low.
March 11, 2026
Pro Medicus Ltd locks in A$40 million U.S. renewals as MedStar adds heart-imaging tools

Pro Medicus Ltd locks in A$40 million U.S. renewals as MedStar adds heart-imaging tools

Pro Medicus’ U.S. unit renewed two imaging software contracts totaling at least A$40 million, including a five-year, A$31 million extension with MedStar Health that adds heart-imaging tools, and a separate A$9 million deal with Zwanger-Pesiri. Both contracts were signed at higher per-transaction fees and expand the company’s presence in the U.S. market.
March 11, 2026
JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead

JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead

A federal judge in Manhattan allowed JPMorgan Chase employees to pursue key claims in a proposed class action alleging the bank mismanaged its health and prescription benefits plan, leading to inflated drug and premium costs. The suit claims the plan paid markups averaging 211% on 366 generic drugs through CVS Caremark. JPMorgan declined to comment. The judge dismissed some fiduciary-duty claims but let prohibited-transaction claims proceed.
March 10, 2026
UnitedHealth Group Faces Fresh Medicare Advantage Pressure Ahead of Barclays Investor Event

UnitedHealth Group Faces Fresh Medicare Advantage Pressure Ahead of Barclays Investor Event

A congressional committee found seniors paid about 10% more in Medicare Part B premiums last year due to alleged overpayments to private Medicare Advantage plans, the Wall Street Journal reported Tuesday. UnitedHealth shares fell 1.4% by midmorning. The company, the largest Medicare Advantage provider, is set to address investors at a Barclays conference later in the day. UnitedHealth has denied previous allegations of aggressive billing practices.
March 10, 2026
Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets

Biohaven Ltd stock whipsaws after FDA exit revives rare-disease bets

Biohaven Ltd shares swung sharply Monday, opening at $11.38, peaking at $12.70, then dropping to $9.91 by 10:55 a.m. EDT, with volume over 3.1 million. The moves followed a leadership change at the FDA, which last year rejected Biohaven’s rare-disease drug Vyglxia, sending shares down over 40%. Biohaven reported a 2025 net loss of $738.8 million and ended December with $322 million in cash.
March 9, 2026
Amazon Launches Connect Health, Pushing AWS Deeper Into Healthcare AI

Amazon Launches Connect Health, Pushing AWS Deeper Into Healthcare AI

Amazon Web Services launched Amazon Connect Health, an AI service for healthcare administration, on Thursday. The tool integrates with Epic electronic health records to verify patients, schedule visits, and generate billing codes. Patient verification and ambient documentation are available now; other features remain in preview. AWS says UC San Diego Health cut call abandonment by 30% using the system.
March 6, 2026
CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares

CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares

CSL’s Seqirus unit has secured a Canadian government contract to supply up to 15 million pandemic flu vaccine doses from its Tullamarine plant if a pandemic is declared. The deal follows an 81% drop in CSL’s half-year profit and a leadership change. Financial terms were not disclosed. CSL has spent about A$738.8 million on share buybacks since launching its on-market program.
March 6, 2026
Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap

Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap

Eli Lilly launched “Employer Connect” to let U.S. employers offer its obesity drug Zepbound at network pharmacies for $449 per dose. Partners include GoodRx, Teladoc Health, and Mark Cuban Cost Plus Drug Company. Lilly shares fell about 2% after the announcement. The company said final out-of-pocket costs will depend on each employer’s cost-sharing model.
March 6, 2026
Amazon debuts ‘agentic AI’ healthcare tool to cut clinic call times and paperwork

Amazon debuts ‘agentic AI’ healthcare tool to cut clinic call times and paperwork

Amazon Web Services on Thursday launched Amazon Connect Health, an AI platform that automates tasks like appointment scheduling and billing by integrating with electronic health records. Patient verification and ambient documentation are available now; other features are in preview. Early use at UC San Diego Health cut call abandonment by up to 60%. AWS said clinicians must review all AI-generated outputs.
March 5, 2026
Bradesco sets March 31 vote on Bradseg spin-off in Bradsaúde healthcare push

Bradesco sets March 31 vote on Bradseg spin-off in Bradsaúde healthcare push

Bradesco filed a distance voting ballot for a March 31 shareholders’ meeting to seek approval for a partial spin-off of Bradseg Participações. The move is part of a plan to transfer health assets into Odontoprev, which would become Bradsaúde. Bradesco’s New York-listed shares fell 6.6% after the filing. Shareholder approval and regulatory clearance are still required.
March 4, 2026
UnitedHealth stock price today: UNH slides as Medicare scrutiny and risk-off trade hit insurers

UnitedHealth stock price today: UNH slides as Medicare scrutiny and risk-off trade hit insurers

UnitedHealth Group shares fell 2.1% to $288.79 Tuesday, tracking losses in major health insurers as Wall Street slid on inflation and Middle East conflict concerns. The Centers for Medicare & Medicaid Services told Elevance it may suspend new enrollments in its Medicare Advantage drug plans over regulatory deficiencies. UnitedHealth filed a new shelf registration and named Dennis Stankiewicz chief accounting officer.
March 3, 2026
UnitedHealth (UNH) stock price holds near $294 as Medicare regulator targets rival Elevance

UnitedHealth (UNH) stock price holds near $294 as Medicare regulator targets rival Elevance

UnitedHealth shares edged up 0.2% to $293.71 Monday as the company disclosed new Medicare Advantage audit risks in its annual report. The SEC filing said some local plans face risk adjustment data validation audits, which can lead to payment clawbacks or fines. UnitedHealthcare served about 8.4 million Medicare Advantage members as of Dec. 31, 2025. Elevance shares dropped 9% after CMS moved to suspend enrollment in some plans.
March 2, 2026

Stock Market Today

  • Valuing CBA Shares Using Dividend Yield and PE Ratio
    May 23, 2026, 12:29 AM EDT. Commonwealth Bank of Australia (CBA) shares trade at $165.67 with a price-to-earnings (PE) ratio of 29.4 times, above the banking sector average of 18 times. Calculating fair value by multiplying CBA's earnings per share ($5.63) by the sector PE suggests a valuation near $102.50, indicating current shares may be overvalued relative to peers. The bank's steady dividend payments, common among Australian banks, support dividend discount model (DDM) approaches to valuation, which factor in expected dividends for estimating intrinsic share price. Investors should consider sector comparisons and stable dividend histories when assessing CBA share investment potential.